- Home
- NCLH vs EXEL Comparison
NCLH vs EXEL Comparison
Compare NCLH & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCLH
- EXEL
- Stock Information
- Founded
- NCLH 1966
- EXEL 1994
- Country
- NCLH United States
- EXEL United States
- Employees
- NCLH N/A
- EXEL N/A
- Industry
- NCLH Marine Transportation
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCLH Consumer Discretionary
- EXEL Health Care
- Exchange
- NCLH Nasdaq
- EXEL Nasdaq
- Market Cap
- NCLH 7.1B
- EXEL 9.8B
- IPO Year
- NCLH 2013
- EXEL 2000
- Fundamental
- Price
- NCLH $17.88
- EXEL $36.50
- Analyst Decision
- NCLH Buy
- EXEL Buy
- Analyst Count
- NCLH 18
- EXEL 18
- Target Price
- NCLH $26.88
- EXEL $37.59
- AVG Volume (30 Days)
- NCLH 15.9M
- EXEL 2.3M
- Earning Date
- NCLH 04-30-2025
- EXEL 05-13-2025
- Dividend Yield
- NCLH N/A
- EXEL N/A
- EPS Growth
- NCLH 120.77
- EXEL 170.77
- EPS
- NCLH 1.77
- EXEL 1.76
- Revenue
- NCLH $9,415,989,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- NCLH $9.38
- EXEL $5.78
- Revenue Next Year
- NCLH $10.38
- EXEL $10.94
- P/E Ratio
- NCLH $10.10
- EXEL $20.74
- Revenue Growth
- NCLH 5.57
- EXEL 18.50
- 52 Week Low
- NCLH $14.21
- EXEL $20.14
- 52 Week High
- NCLH $29.29
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- NCLH 52.85
- EXEL 45.67
- Support Level
- NCLH $16.78
- EXEL $35.34
- Resistance Level
- NCLH $17.72
- EXEL $40.26
- Average True Range (ATR)
- NCLH 0.69
- EXEL 1.21
- MACD
- NCLH 0.28
- EXEL -0.09
- Stochastic Oscillator
- NCLH 88.93
- EXEL 29.79
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 66,500). It operates 32 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 41,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.